香港2026年9月14日 /美通社/ -- KLN Logistics Group Limited（「KLN」；股份代號0636.HK）與新翔集團有限公司（「新翔集團」；股份代號S58.SI）聯合宣布，KLN旗下附屬公司KLN Freight International Limited（「KLN Freight」）與全球領先的航空貨運處理服務供應商新翔集團簽署合作備忘錄，探討策略合作。此項合作旨在促進環球供應鏈互聯互通、提升營運效率，並為環球客戶構建創新物流解決方案。

此次策略合作將結合KLN的貨運代理及物流專業能力，與新翔集團的全球網絡及航空貨運處理專長，共同開發解決方案，並將其拓展至雙方在亞洲、歐美的綜合網絡，提升端到端供應鏈的互聯性與效率。

作為合作的初步階段，KLN與新翔集團將聚焦於增值服務組合下的兩項策略舉措，包括提供端到端溫控處理解決方案，支援敏感貨物的運輸和儲存；以及為具時效要求的貨運提供加急處理服務，確保運送速度、精準度與可靠性。

KLN執行董事及首席營運主管黃兆龍表示：「對於具時效要求且敏感的醫療保健貨運而言，供應鏈中的每個環節均對保障病人安全和維持服務穩定性至關重要。透過是次合作備忘錄，我們與新翔集團的合作將充分發揮雙方互補優勢，強化網絡韌性、提升貨運可視性，並提高環球營運的服務標準。我們致力提供更快捷、可靠及可持續的物流解決方案，為環球客戶帶來更大保障、靈活性及價值。」

新翔集團首席商務官 Martin Holme表示：「是次合作體現新翔集團致力於透過物流生態系統內的緊密合作，以創造價值。憑藉我們在提升貨運可視性、優化營運流程以及支援具時效要求貨運方面的經驗，我們期待與KLN攜手合作開發能為客戶提供更高效率及卓越服務的解決方案。新加坡將成為率先推行這些舉措的站點，並作為啟動基地，將解決方案拓展至雙方的全球網絡。」

關於KLN Logistics Group Limited（股份代號0636.HK）

KLN是紮根亞洲的國際第三方物流服務供應商，致力提供以客戶為中心的端到端供應鏈解決方案，連繫各地市場，促進環球貿易，為全球眾多百強品牌及《財富》世界500強企業在不同行業所信賴的合作夥伴。KLN 的辦事處遍布全球59個國家及地區，業務涵蓋綜合物流、國際貨運、以及電子商貿和工業項目物流等。KLN自2023年起為全球第一大亞洲至美國跨太平洋貿易航線無船承運商，以及在全球第三方物流供應商中排名第20位（Armstrong & Associates，2026年）。KLN於香港聯合交易所上市，2025 年收入*逾 560 億港元，並為恒生可持續發展企業基準指數成份股。了解更多，請瀏覽：www.kln.com

* 僅就持續經營業務而言

關於新翔集團有限公司

新翔集團有限公司 （新加坡證券交易所代碼：S58）總部位於新加坡，是全球領先的航空貨運服務供應商之一，也是亞洲領先的航空配餐服務提供商。新翔口岸服務提供一系列航空貨運及地勤服務，包括乘客服務、停機坪及行李處理、航空安保服務、飛機清潔及航空洗衣服務。新翔食品產業則為航空公司及機構團體提供餐飲服務，並運營具備大規模食品生產及配送能力的中央廚房，可供應多元化餐飲產品。新翔業務遍及亞太、美洲、歐洲、中東及非洲地區，為全球貿易、旅行和美食體驗構建緊密互聯的網絡。繼2023年收購環美航務後，新翔與環美航務的聯合網絡已覆蓋27個國家、超過225個運營站點，服務於佔全球航空貨運總量50%以上的重要貿易航線。新翔自2000年5月起在新加坡證券交易所上市。欲了解更多信息，請訪問：www.sats.com.sg

HONG KONG, Sept. 14, 2026 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) and SATS Ltd. ('SATS'; Stock Code S58.SI) jointly announced that KLN Freight International Limited ('KLN Freight'), a subsidiary of KLN, has signed a Memorandum of Understanding (MOU) with SATS, one of the world's leading providers of air cargo handling services. The parties will explore strategic collaborations to strengthen the global supply chain connectivity, improve operational efficiency and develop innovative logistics solutions for customers worldwide.

The strategic partnership will combine KLN's freight forwarding and logistics capabilities with SATS' global network and air cargo handling expertise to jointly develop and scale solutions across their combined networks in Asia, Europe and the Americas, creating greater connectivity and efficiency across the end-to-end supply chain.

As an initial step, KLN and SATS will focus on two strategic initiatives under their value-added service offerings: end-to-end temperature-controlled handling solutions to support the transport and storage of sensitive cargo and the expedited handling of time-critical shipments that require speed, precision and reliability.

Wong Siew Loong, Executive Director and Chief Operating Officer of KLN, said, "For time-critical and sensitive cargo such as healthcare shipments, every touchpoint in the supply chain is critical to safeguarding patient safety and service continuity. Through this MOU, our partnership with SATS leverages our complementary strengths to reinforce network resilience, enhance shipment visibility and advance service standards across our global operations. We are committed to delivering faster, more reliable and sustainable logistics solutions that provide greater assurance, agility and value for customers worldwide."

Martin Holme, Chief Commercial Officer of SATS, said, "This partnership reflects SATS' commitment to creating value through closer collaboration across the logistics ecosystem. Building on our experience in improving cargo visibility, streamlining operations and supporting time-critical shipments, we look forward to working with KLN to develop solutions that deliver greater efficiency and service excellence for customers. Singapore will be the first station for these initiatives, serving as a launchpad for solutions that can be scaled across our respective global networks."

About KLN Logistics Group Limited (Stock Code 0636.HK)

KLN is an Asia-rooted, global 3PL delivering customer-centric, end-to-end supply chain solutions that connect markets and power global trade, as a trusted partner to many of the top 100 global brands and Fortune Global 500 companies across a wide spectrum of industries. With a presence across 59 countries and territories, KLN offers integrated logistics, international freight forwarding, e-commerce and industrial project logistics solutions. KLN has been the global No. 1 Trans-Pacific NVOCC from Asia to the US since 2023 and ranks No. 20 among Global 3PLs (Armstrong & Associates, 2026). Listed on the Hong Kong Stock Exchange, KLN generated revenue* of over HK$56 billion in 2025 and is a constituent of the Hang Seng Corporate Sustainability Benchmark Index. Learn more at www.kln.com

* For continuing operations only

About SATS Ltd.

Headquartered in Singapore, SATS Ltd. (SGX: S58) is one of the world's leading providers of air cargo handling services and Asia's leading airline caterer. SATS Gateway Services provides airfreight and ground handling services including passenger services, ramp and baggage handling, aviation security services, aircraft cleaning and aviation laundry. SATS Food Solutions serves airlines and institutions, and operates central kitchens with large-scale food production and distribution capabilities for a wide range of cuisines. SATS is present in the Asia-Pacific, the Americas, Europe, the Middle East and Africa, powering an interconnected world of trade, travel and taste. Following the acquisition of Worldwide Flight Services (WFS) in 2023, the combined SATS and WFS network operates over 225 stations in 27 countries. These cover trade routes responsible for more than 50% of global air cargo volume. SATS has been listed on the Singapore Exchange since May 2000. For more information, please visit www.sats.com.sg

Market focus is shifting from sentiment back to fundamentals, CLSA said in a research report. The broker's "At a Clip" China strategy report revolves around three major themes: AI monetization, China biotech catalysts, and livestock supply discipline. The broker viewed investors should focus on earnings delivery, identifiable catalysts, and companies with cost or execution advantages.

On agentic AI, the broker said computing power demand continues to be underpinned by AI infrastructure spending, but the next round of re-rating will depend on commercialization validation beyond coding applications. Semiconductor equipment remains a high-conviction beneficiary sector. Forecasts for the global wafer fab equipment (WFE) market were revised upward, with 2026 and 2027 estimates raised by about 14% and 30% respectively, while the market could further reach around USD200 billion in 2028.

In cloud computing, the broker projected the global public cloud market to double to USD2.3 trillion by 2028. The broker believed full-stack AI service providers are best positioned to capture opportunities. BABA-W (09988.HK) is viewed as being in the strongest position in China to benefit from this long-term structural trend, while TENCENT (00700.HK) has advantages in consumer agents and enterprise SaaS through the WeChat ecosystem, world models, and video and gaming data. The broker also noted that earnings results and guidance from NVIDIA (NVDA.US) reinforced visibility for medium-term computing power demand, and foresaw TRIP.COM-S (09961.HK) is more resilient than US-funded OTA operators.

In biotech, the broker said fundamentals' explanatory power over sector performance recovered to more than 54%, while business development (BD) activities in 4Q26 and upcoming clinical data releases will serve as near-term catalysts. China-related outbound licensing deals reached about USD99.7 billion in 1H26, reinforcing China's role in global drug innovation. On the clinical front, the World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) meetings were expected to amplify valuation and partnership momentum. Data updates from China-originated assets such as AKESO (09926.HK) and SKB BIO (06990.HK) are worth monitoring. BEONE MEDICINES (06160.HK), CSPC PHARMA (01093.HK) and HANSOH PHARMA (03692.HK) were also mentioned in relation to licensing or clinical pipelines.

Overall, under the three major themes, the market is returning to a stage where earnings realization serves as the basis for pricing.
~

AASTOCKS Financial News
Website: www.aastocks.com

Multiple individuals were suspected to have had their credit cards stolen to order iPhones. In response to media inquiries, an Apple spokesperson said that all received orders would undergo review before processing. The company is expediting the identification and cancellation of any potentially submitted fraudulent transactions.

Apple's iPhone 18 Pro series officially began pre-orders on Saturday (12th). Police received reports from more than 700 people during Saturday and Sunday (13th), alleging that their credit cards were suspected to have been misused for online phone purchases, involving approximately HKD14.7 million. The largest single case involved about HKD114,000. No arrests have been made so far.
~

AASTOCKS Financial News
Website: www.aastocks.com

CHENGDU, China, Sept. 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational study of its novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate (ADC) trastuzumab botidotin (舒泰莱^®) in HER2-positive unresectable or metastatic breast cancer (BC) have been published in Journal of Clinical Oncology (JCO, impact factor (IF)=44.7). Professor Xichun Hu and Professor Hongxia Wang of Fudan University Shanghai Cancer Center, and Dr. Junyou Ge, Director of the National Engineering Research Center of Targeted Biologics act as the co-senior authors. Professor Jian Zhang of Fudan University Shanghai Cancer Center, Professor Quchang Ouyang of Hunan Cancer Hospital, Professor Qingyuan Zhang of Harbin Medical University Cancer Hospital, Professor Huihui Li of Cancer Hospital of Shandong First Medical University, and Professor Xu Wang of Tianjin Medical University Cancer Institute and Hospital act as the co-first authors. These findings had previously been selected as a Late-Breaking Abstract (LBA) and presented as an oral presentation at the 2025 European Society for Medical Oncology (ESMO) Congress.

This randomized, open-label, multicenter phase III study was designed to evaluate the efficacy and safety of trastuzumab botidotin monotherapy versus trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic BC who had received prior trastuzumab and taxane-containing regimens. A total of 365 patients were randomized 1:1 to receive trastuzumab botidotin or T-DM1. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review (BICR), and secondary endpoints included overall survival (OS), objective response rate (ORR), and duration of response (DoR).

As of the data cutoff date of April 26, 2025, with a median follow-up of 14.9 months, efficacy results showed:

• Median PFS was significantly prolonged in the trastuzumab botidotin group compared with the T-DM1 group (11.1 months vs. 4.4 months; hazard ratio (HR) = 0.39) (Figure A), meeting the primary endpoint of the study; consistent PFS benefit was observed across all prespecified subgroups (Figure B).
   
•  Trastuzumab botidotin group demonstrated deeper and more durable tumor responses compared with T-DM1 group, with an ORR of 76.9% vs. 53.0% and a median DoR of 12.2 months vs. 5.7 months (Figure C).
  
  
•  OS data were not mature in both groups, but an OS benefit trend was observed in trastuzumab botidotin group, demonstrating a 38% reduction in the risk of death (Figure D).

In terms of safety, patients in the trastuzumab botidotin group had a low incidence of interstitial lung disease (ILD), and the incidences of hematologic, hepatic, and gastrointestinal toxicities were notably lower than those in the T-DM1 group, along with lower rates of serious adverse events (SAEs) and treatment discontinuations. The most common treatment-related adverse events (TRAEs) in trastuzumab botidotin group were ocular events, which could be recovered or reversed after management with standardized strategies.

The publication of the phase III results for trastuzumab botidotin in Journal of Clinical Oncology marks a major international academic breakthrough for a domestically developed HER2 ADC backed by high-level clinical evidence. This is the first phase III trial in China for a HER2 ADC compared head-to-head with T-DM1 with positive results. The data showed that trastuzumab botidotin demonstrated improvements in key efficacy endpoints including PFS, ORR, and DoR, along with a favorable safety profile. Based on these positive results, trastuzumab botidotin has been approved by China's National Medical Products Administration (NMPA) for the treatment of second-line or later HER2-positive BC, becoming the first domestically developed HER2 ADC approved for this indication in China and providing a new treatment option for patients with HER2-positive advanced breast cancer.

About Trastuzumab botidotin(舒泰莱^®)

Trastuzumab botidotin is a differentiated HER2 ADC to treat advanced HER2+ solid tumors. As an innovative HER2 ADC developed by the Company, it conjugates a novel, monomethyl auristatin F (MMAF) derivative (a highly cytotoxic tubulin inhibitor, Duo-5) via a stable, enzyme-cleavable linker to a HER2 monoclonal antibody with a DAR of 2. Trastuzumab botidotin specifically binds to HER2 on the surface of tumor cells and is internalized by tumor cells, releasing the toxin molecule Duo-5 inside the cell. Duo-5 induces tumor cell cycle arrest in the G2/M phase, leading to tumor cell apoptosis. After targeting HER2, trastuzumab botidotin can also inhibit the HER2 signaling pathway; it has antibody-dependent cell-mediated cytotoxicity (ADCC) activity.

Based on the results of a multi-center, randomized, open-label, controlled Phase 3 KL166-III-06 study, trastuzumab botidotin was approved for marketing by the NMPA for adult patients with unresectable or metastatic HER2 positive BC who have received one or more prior anti-HER2 therapy. At a pre-specified interim analysis, trastuzumab botidotin monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of PFS as assessed by the BICR compared with T-DM1; the beneficial trend for OS of trastuzumab botidotin was also observed.

Currently, the Company has initiated an open, multi-center Phase 2 clinical study of trastuzumab botidotin in the treatment of HER2+ unresectable or metastatic BC that previously received a topoisomerase inhibitor payload ADC.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 2 projects with 3 indications are in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/. 

成都2026年9月14日 /美通社/ -- 四川科倫博泰生物醫藥股份有限公司(下稱「科倫博泰」或「公司」 6990.HK)宣佈，新型靶向人類表皮生長因子受體2 (HER2)抗體偶聯藥物(ADC)博度曲妥珠單抗(舒泰萊^®)治療HER2陽性不可切除或轉移性乳腺癌(BC)的III期註冊性研究結果發表於國際腫瘤學權威期刊《臨床腫瘤學雜誌》(Journal of Clinical Oncology，影響因子(IF)=44.7)。復旦大學附屬腫瘤醫院胡夕春教授、王紅霞教授及生物靶向藥物國家工程研究中心主任葛均友博士為共同資深作者，復旦大學附屬腫瘤醫院張劍教授、湖南省腫瘤醫院歐陽取長教授、哈爾濱醫科大學附屬腫瘤醫院張清媛教授、山東第一醫科大學附屬腫瘤醫院李慧慧教授和天津醫科大學腫瘤醫院汪旭教授為共同第一作者。該研究結果此前已入選2025年歐洲腫瘤內科學會(ESMO)大會突破性摘要(LBA),並以口頭報告的形式發佈。

該研究是一項隨機、開放、多中心III期臨床研究，旨在評估博度曲妥珠單抗單藥對比恩美曲妥珠單抗(T-DM1)在既往接受過曲妥珠單抗和紫杉類治療的HER2陽性不可切除或轉移性BC患者中的療效和安全性。共365例患者按1:1隨機分配接受博度曲妥珠單抗或T-DM1治療，主要終點為盲態獨立中心評估(BICR)評估的無進展生存期(PFS)，次要終點包括總生存期(OS)、客觀緩解率(ORR)、緩解持續時間(DoR)等。

數據截至2025年4月26日，中位隨訪時間為14.9個月。療效數據顯示：

• 博度曲妥珠單抗組相較T-DM1組顯著延長中位PFS(11.1個月 vs 4.4個月；風險比(HR)=0.39)  (Figure A)，已達到研究的主要終點；且在所有預設亞組中均能觀察到一致的PFS獲益 (Figure B)；
• 博度曲妥珠單抗組相較T-DM1組展現出更深、更持久的腫瘤緩解效果，ORR為76.9% vs 53.0%，中位DoR為 12.2個月vs 5.7個月 (Figure C)。
• 兩組OS數據均未成熟，但博度曲妥珠單抗組已觀察到OS獲益趨勢，死亡風險降低38% (Figure D)；

安全性方面，博度曲妥珠單抗組患者的間質性肺病(ILD)發生率低，血液、肝臟及胃腸道毒性發生率明顯低於T-DM1組，嚴重不良事件(SAE)發生率及停藥率亦更低。此外，博度曲妥珠單抗組最常見的治療相關不良事件(TRAE)為眼部AE，可通過標準化策略管理後恢復或緩解。

博度曲妥珠單抗III期研究成果發表於《臨床腫瘤學雜誌》，意味著國產HER2 ADC依託高水平的臨床證據在國際學術領域取得了重要突破。該研究是中國首個HER2 ADC頭對頭對比T-DM1取得陽性結果的III期臨床研究，其數據表明，博度曲妥珠單抗在PFS、ORR及DoR等關鍵療效終點顯示出優勢，並表現出良好的安全性特徵。憑藉此積極結果，博度曲妥珠單抗已獲中國國家藥品監督管理局(NMPA)批准治療二線及以上HER2陽性BC患者，成為中國首個獲批該項適應症的國產HER2 ADC，為HER2陽性晚期BC患者提供了新的治療選擇。

關於博度曲妥珠單抗(舒泰萊^®)

博度曲妥珠單抗是一款用於治療晚期HER2陽性實體瘤的差異化HER2 ADC。作為一款由本公司開發的創新HER2 ADC，其通過穩定的酶可裂解連接子將新型單甲基奧瑞他汀F(MMAF)衍生物（高細胞毒性微管蛋白抑制劑Duo-5）與HER2單克隆抗體偶聯，藥物抗體比率為2。博度曲妥珠單抗特異性地結合腫瘤細胞表面的HER2，並被腫瘤細胞內吞，在胞內釋放毒素分子Duo-5。Duo-5誘導腫瘤細胞週期阻滯在G2/M期，引起腫瘤細胞凋亡。博度曲妥珠單抗靶向結合HER2後也可抑制HER2介導的信號通路；其具有抗體依賴細胞介導細胞毒作用(ADCC)活性。

基於一項多中心、隨機、開放標籤、對照III期KL166-III-06研究結果，博度曲妥珠單抗獲NMPA批准用於既往接受過一種或一種以上抗HER2藥物治療的不可切除或轉移性HER2陽性成人BC患者。在預設的期中分析中，與T-DM1相比，博度曲妥珠單抗單藥在主要研究終點——BICR評估的PFS方面實現統計學意義和臨床意義的顯著改善；亦觀察到博度曲妥珠單抗OS的獲益趨勢。

目前，本公司已啟動博度曲妥珠單抗用於治療既往接受過有效載荷為拓撲異構酶抑制劑ADC治療的HER2陽性不可切除或轉移性BC的開放、多中心II期臨床研究。

關於科倫博泰

四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰」，股票代碼：6990.HK)是科倫藥業控股子公司，專注於創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求，重點佈局腫瘤、自身免疫和代謝等重大疾病領域，建設國際化藥物研發與產業化平台，致力於成為在創新藥物領域國際領先的企業。公司目前擁有30餘個重點創新藥項目，其中4個項目8個適應症已獲批上市，2個項目3個適應症處於NDA階段，10余個項目正處於臨床階段。公司成功構建了享譽國際的專有ADC及新型偶聯藥物平台OptiDC™，已有2個ADC項目5個適應症獲批上市，多個ADC或新型偶聯藥物產品處於臨床或臨床前研究階段。瞭解更多，請訪問：https://www.kelun-biotech.com/。 

During the current earnings season, suppliers with exposure to Apple Inc. (AAPL.US) and the high-end segment demonstrated relatively stronger resilience, while low-end and mid-range Android smartphones were hit hard by rising component prices, UOB Kay Hian said in a report.

The broker expected the pressure to persist through 2027 and preferred Apple supply chain stocks over Android supply chain names, given their more resilient shipments, margins and ASP.

The broker was also bullish on manufacturers that have meaningfully diversified into AI devices and AI servers, citing these businesses' meaningful buffer. The broker maintained an Overweight rating on the sector and preferred AI hardware over handset supply chain stocks.

SUNNY OPTICAL (02382.HK), Q TECH (01478.HK) and AAC TECH (02018.HK) were all expected to chart high double-digit growth in related businesses in 2026. AI infrastructure components were estimated to begin ramping up from 2H26.

The broker's ratings and target prices for Apple supply chain stocks and AI hardware stocks are listed below:

Stock|Rating|TP
SUNNY OPTICAL (02382.HK)|Buy|HKD106
XIAOMI-W (01810.HK)|Hold|HKD26.2
AAC TECH (02018.HK)|Buy|HKD47.8
Q TECH (01478.HK)|Hold|HKD6.7
BYD ELECTRONIC (00285.HK)|Sell|HKD14.5
COWELL (01415.HK)|Buy|HKD48
LENS (06613.HK)|Buy|HKD43.1
~

AASTOCKS Financial News
Website: www.aastocks.com

Tesla, Inc. (TSLA.US) CEO Elon Musk said the company will unveil the long-delayed next-generation Roadster electric sports car on October 1, nearly a decade after the previous-generation Roadster.

The next-generation Roadster will reportedly feature a redesigned model, and a limited-edition version developed in collaboration with SpaceX (SPCX.US), equipped with "cold gas thrusters", may also be announced at the launch event.
~

AASTOCKS Financial News
Website: www.aastocks.com

Anthropic is in talks to bring in NVIDIA Corporation (NVDA.US) as a cornerstone investor, with the latter considering an investment of up to USD10 billion, Reuters, citing sources, reported.

Anthropic is reportedly seeking to raise USD100 billion in the IPO, with a valuation that could reach about USD2 trillion. Bringing in NVIDIA as a cornerstone investor may strengthen investor confidence in the listing.
~

AASTOCKS Financial News
Website: www.aastocks.com

Apple's iPhone 18 Pro series officially kicked off pre-orders on Saturday (12th). During Saturday and Sunday (13th), police received reports from more than 700 people alleging that their credit cards were suspected to have been fraudulently used to purchase phones online, involving around HKD14.7 million. The largest single case involved about HKD114,000. No arrests have been made so far.

A spokesperson for the Hong Kong Monetary Authority said credit card transactions have always required effective measures to ensure security and protect customer interests. Individual merchants may choose not to use or may suspend additional authentication arrangements, such as in-app authentication or one-time passwords, due to operational considerations. In such cases, merchants must bear responsibility and financial losses arising from unauthorized transactions.

The spokesperson emphasized that cardholders should carefully check transaction records. If they suspect or discover unauthorized use of their credit cards, they should notify the card-issuing bank as soon as possible, including immediately disabling the relevant credit card through online banking services. Generally, if a bank credit card account is used for unauthorized transactions and the cardholder has not committed fraud or gross negligence, the cardholder will not be liable for the unauthorized transactions.

An HSBC spokesperson said the bank had noted online discussions indicating that customers of different banks suspected their credit cards had been fraudulently used to order mobile phones. The bank will investigate for customers and, where applicable, initiate chargeback mechanisms according to credit card organization rules.

BOC Hong Kong reminded customers to immediately log into mobile banking to block the relevant credit card if they discover unauthorized transactions. The bank said its credit card customers are protected by refund mechanisms, and customers will not be liable for any verified unauthorized credit card transactions.

A Standard Chartered spokesperson said customers who discover any unauthorized transactions should notify the bank and report the case to police as soon as possible. Customers may also instantly block their credit cards through online banking or SC Mobile. The bank will immediately investigate and follow up according to established procedures and, where applicable, submit refund applications to relevant credit card organizations. If investigations confirm that the transactions were unauthorized by the cardholder, the cardholder will not be responsible for the related payments.

A Hang Seng Bank spokesperson said customers who discover suspicious credit card transactions should immediately freeze their credit cards through the Hang Seng Bank mobile application or contact the bank. During the investigation period, Hang Seng will support affected customers and, where applicable, initiate chargeback mechanisms according to credit card organization rules. The bank reiterated that if customers have used their credit cards reasonably and prudently, the bank will provide full assistance in completing refund procedures.
~

AASTOCKS Financial News
Website: www.aastocks.com